Cisplatin Promotes Immunosuppression in Ovarian Cancer by Enhancing miR-181a-5p-Enriched Extracellular Vesicles to Drive Regulatory T Cell Differentiation
{{output}}
Although cisplatin (CDDP) is widely employed in combination immunotherapy, no CDDP-based regimen has shown a survival benefit when treating the ovarian cancers. This is mainly because the impact of CDDP on immunotherapy is not fully understood. A critical gap ... ...
